Invention Grant
![Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy](/docs/US/2023-05-23/US11654133B2/abs.jpg.600x600.jpg)
- Patent Title: Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy
-
Application No.: US17037932Application Date: 2020-09-30
-
Publication No.: US11654133B2Publication Date: 2023-05-23
- Inventor: Marc Kamin , Laurent Vernillet
- Applicant: SK BIOPHARMACEUTICALS CO., LTD.
- Applicant Address: KR Gyeonggi-do
- Assignee: SK BIOPHARMACEUTICALS CO., LTD.
- Current Assignee: SK BIOPHARMACEUTICALS CO., LTD.
- Current Assignee Address: KR Gyeonggi-do
- Agency: Harness, Dickey & Pierce, P.L.C.
- Main IPC: A61K31/41
- IPC: A61K31/41 ; A61K31/55 ; A61P25/08 ; A61K31/4166 ; A61K31/515 ; A61K31/53
![Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy](/abs-image/US/2023/05/23/US11654133B2/abs.jpg.150x150.jpg)
Abstract:
The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.
Public/Granted literature
- US20210008033A1 Use Of [(1R)-1-(2-Chlorophenyl)-2-(Tetrazol-2-YL)Ethyl] Carbamate In Combination Therapy Public/Granted day:2021-01-14
Information query
